We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Urinary Pathogen Resistance Increased Post Kidney Transplant

By LabMedica International staff writers
Posted on 31 May 2017
A urinary tract infection (UTI) is the most common complication after kidney transplantation and it can cause severe sepsis and transplant loss. More...
Emergence of drug resistance among gram-negative urinary pathogens is the current challenge for urinary tract infection treatment after kidney transplantation.

The incidence of drug-resistant urinary pathogens seems to be increasing and has become a rising therapeutic challenge for clinicians. The antibiotic exposure after kidney transplantation is elevated due to treatment of asymptomatic bacteriuria (ASB) and pneumocystis pneumonia (PCP) prophylaxis.

Scientists at the University Hospital Essen analyzed the antimicrobial susceptibility of gram-negative urinary pathogens after kidney transplantation from 2009 to 2012 at their Transplant Outpatient Clinic. Kidney transplant patients received regular follow up examinations after transplantation. Midstream urines were examined for bacteriuria at each follow up visit. From 2009 to 2012 a large number of 15,741 urine samples were obtained from 859 patients (324 (38%) male, 535 (62%) female).

Samples were cultured using standard media with semi quantification. Cultured bacteria were identified by matrix assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF) and susceptibility testing was performed using the VITEK system. Patients suffering UTI or ASB got empirical treatment according to the local UTI treatment strategy. All patients were treated with low-dose trimethoprim-sulfamethoxazole for pneumocystis (PCP) prophylaxis for at least six month after transplantation.

The team reported that the most frequently detected gram-negative bacteria were Escherichia coli, 1,109 (37%), Klebsiella spp. 242 (8%) and Pseudomonas aeruginosa 136 (4.5%). Klebsiella spp. showed a significant increase of resistance to trimethoprim-sulfamethoxazole by 19%, ciprofloxacin by 15% and ceftazidime by 17%. E.coli and P. aeruginosa isolates presented no significant differences of antimicrobial susceptibility to the analyzed antibiotics. In 51 renal transplant patients, urosepsis due to gram-negative pathogens (E.coli, Klebsiella spp., and P. aeruginosa) was diagnosed from 2009 to 2012.

The authors concluded that there was an increase of antimicrobial resistance to commonly used antibiotic agents among gram-negative uropathogens isolated from kidney transplant recipients during an observation period of four years. Antimicrobial resistance of Klebsiella spp. increased significant to trimethoprim-sulfamethoxazole, ciprofloxacin and ceftazidime. The study was published on May 19, 2017, in the journal BMC Nephrology.


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
ESR Analyzer
miniiSED™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.